To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Can a virus fight cancer?
Canadian Cancer Society grants new funding
27-07-2012: Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.
Viruses that selectively target and kill cancer cells — called oncolytic viruses — are an exciting new avenue for treating cancer because healthy cells are spared and side effects are reduced. The problem is that many tumors are able to protect themselves by unleashing defense mechanisms that disarm these viruses.
Two researchers are each tackling this problem with creative approaches that involve delivering the viruses in combination with new drugs to make the treatments more effective than either would be alone.
Dr Jean-Simon Diallo of the Ottawa Hospital Research Institute is receiving $200,000 to study the use of a specially engineered virus given in combination with a novel type of drug to help the virus overcome the tumor's defense mechanisms. Using a unique mathematical model, he will use results from this newly funded research to predict the success of other drug-virus combinations.
Dr Diallo's highly innovative research proposes a creative solution to disarming tumors' defense mechanisms with novel drugs, while also accelerating development of oncolytic viruses through mathematical modeling.
Dr Robert Korneluk of the Children's Hospital of Eastern Ontario is receiving $200,000 to study whether the defense mechanisms that tumors use to protect themselves from viruses can be turned against them.
Dr Korneluk is studying a group of experimental drugs that are highly effective in killing cancer cells, particularly in the presence of a specific compound. This compound is produced both by the immune system and by cancer cells and can result in actually protecting the tumour cells from viruses. In Dr Korneluk's innovative project, he will test whether, when given in combination with a cancer-killing virus, these experimental drugs can effectively destroy cancer cells.
Watchlist
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 7Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 8Sanofi-aventis to acquire Oenobiol
- 9MIV-210 - a potential drug against hepatitis B and HIV - enters phase II
- 10Vivacta Initiates Development of Point of Care Test for Vitamin D
- An end to chasing structures that were never there
- Psychiatric disorders linked to a protein involved in the formation of long- ...
- Study finds racial and ethnic disparities in usage of specialty services for ...
- Bacterium breaks down grass into biofuel
- Presentation of the 2013 Eppendorf Award for Young European Investigators
